

5 USE OF MONOCLONAL ANTIBODIES THAT DEFINE
 UNIQUE MENINGOCOCCAL B EPITOPES IN THE
 PREPARATION OF VACCINE COMPOSITIONS

Abstract of the Disclosure

10 Novel bactericidal antibodies against *Neisseria*
 meningitidis serogroup B ("MenB") are disclosed. The
 antibodies either do not cross-react or minimally cross-
 react with host tissue polysialic acid and hence pose
 minimal risk of autoimmune activity. The antibodies are
15 used to identify molecular mimetics of unique epitopes
 found on MenB or *E. coli* K1. Examples of such peptide
 mimetics are described that elicit serum antibody capable
 of activating complement-mediated bacteriolysis of MenB.
 Vaccine compositions containing such mimetics can be used
20 to prevent MenB or *E. coli* K1 disease without the risk of
 evoking autoantibody.

25

30

35